FEMY News

Latest breaking news and updates for FEMY stock.

Track all markets on TradingView

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

(NASDAQ:FEMY) --Existing investors, including Femasys’ largest shareholders, reaffirm confidence in Femasys’ strategy for growth and impact in women’s health-- ATLANTA, Sept. 02, 2025 (GLOBE NEW...

How does this financing round position Femasys relative to competitors in the women’s reproductive‑health market and could it affect market share forecasts? What are the specific commercialization milestones and timelines for the fertility and birth‑control pipelines following this funding? How will the $8 million financing influence Femasys’ cash runway and dilution expectations?
Financing
13 days ago
Read more globenewswire

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide,...

How does the offering price and structure (including the $0.5151 price for officer shares) compare to recent equity raises by peer biotech companies, and what does that suggest for near‑term price pressure? What are the specific uses of the $8 million proceeds and how will they impact the company’s cash runway and upcoming product milestones? How will the dilution from the 10,434,586 shares/pre‑funded warrants and accompanying warrants affect FEMY’s earnings per share and existing shareholders?
Equity offering
20 days ago
Read more globenewswire

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertilit...

Will the regulatory approval trigger any short‑term price movement or trigger a buy‑signal based on typical volume and volatility patterns? What is the expected market share gain for FemBloc in the UK compared to existing permanent birth control options and competitors? How will the MHRA approval of FemBloc affect Femasys' projected revenue and earnings guidance for the next quarters?
Regulatory
26 days ago
Read more globenewswire

Femasys Announces Second Quarter Financial Results for 2025

-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical ...

What are the implications for the company's long‑term growth strategy and potential M&A or partnership opportunities in the fertility sector? How might the recent results influence institutional and retail sentiment toward the stock, and what could be the short‑term trading opportunities? What is the projected timeline for achieving profitability or positive cash flow from the fertility portfolio?
Earnings
about 1 month ago
Read more globenewswire